The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses

Autor: Yuanxun Yang, Lei Yu, Zejuan Sheng, Hui Lin, Zuyi Weng, Wei Song, Bei Cao, Yu Zhao, Yingsheng Gao, Shumao Ni, Huimin Wang, Tingting Ma, Lei Huang, Caixia Sun, Juan Li

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

Introduction: TT-01025-CL is an oral, irreversible small molecule that potently inhibits vascular adhesion protein-1 (VAP-1) for the treatment of inflammation associated with non-alcoholic steatohepatitis (NASH). The objectives of this study were to

Externí odkaz: https://doaj.org/article/47785d45a55d49a98682375be448be83

Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice

Autor: Minyi Qian, Qianqian Lyu, Yujie Liu, Haiyang Hu, Shilei Wang, Chuyue Pan, Xubin Duan, Yingsheng Gao, Lian-wen Qi, Weizhi Liu, Lirui Wang

Publikováno v: Marine Drugs, Vol 17, Iss 7, p 391 (2019)

Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it. Chitosan oligosaccharide (COS) is widely known to have various biological effects, and in this study we aimed to evaluate the liver-

Externí odkaz: https://doaj.org/article/28ca3b7f72c348499442c5d4a32cb6fd

Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease

Autor: Chengjie Shan, Wenxin Jia, Minyi Qian, Lirui Wang, Bernd Schnabl, Dalei Wu, Nan Zhang, Yinan Zhang, Danyang Zhao, Meiling Zhang, Song Yang, Yufei Zhang, Yingsheng Gao, Quan Zhang, Chuyue Pan, Xu Shen, Jun Liu, Pengpeng Cai

Publikováno v: Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology, Vol 13, Iss 1, Pp 233-256 (2022)

Background & Aims The ligand-activated transcription factor, aryl hydrocarbon receptor (AHR) can sense xenobiotics, dietary, microbial, and metabolic cues. Roles of Ahr in intestinal epithelial cells (IECs) have been much less elucidated compared wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec51e69e7577835c46cf4ef5134d8f2
https://doi.org/10.1016/j.jcmgh.2021.08.014

WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice

Autor: Lirui Wang, Minyi Qian, Haiyang Hu, Xubin Duan, Lian-wen Qi, Shuo-quan Zhang, Jun Liu, Hui-bin Zhang, Shilei Wang, Jinpei Zhou, Yingsheng Gao, Chuyue Pan, Qiangqiang Wei

Publikováno v: Acta Pharmacologica Sinica

The global prevalence of nonalcoholic steatohepatitis (NASH) increases incredibly. NASH ends up to advanced liver disease, which is highly threatening to human health. Currently, treatment of NASH is very limited. Acetyl-CoA carboxylases (ACC1/ACC2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a8eca5b69456ed9d5b6453e91a6291
https://doi.org/10.1038/s41401-019-0310-0

TP53 Mutations Promote Immunogenic Activity in Breast Cancer

Autor: Cai Chen, Yingsheng Gao, Xiaosheng Wang, Zhixian Liu, Lirui Wang, Zehang Jiang

Publikováno v: Journal of Oncology, Vol 2019 (2019)
Journal of Oncology

BackgroundAlthough immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no any immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying the BC patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda173eea6ec4f4dccf5af476ade7b56
https://doi.org/10.2139/ssrn.3260781